Abstracts tagged "complement"

Abstract Number: 0608 • ACR Convergence 2024
Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Chau-Ching Liu⁵, Nicole Wilson⁵, Susan Manzi⁵ and Tyler O'Malley⁶, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Exagen, Vista, CA
Background/Purpose: Cell bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte C4d (BC4d) demonstrate increased diagnostic accuracy compared to conventional SLE markers (anti-dsDNA,…
Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 0617 • ACR Convergence 2024
Hereditary C1q Deficiency Is Associated with Type 1 Interferon-pathway Activation and a High Risk of Central Nervous System Inflammation
Clément triaille¹, Neha Mohan Rao², Gillian Rice³, Luis Seabra⁴, Sutherland Fraser⁵, Vincent Bondet⁶, Darragh duffy⁶, Andrew Gennery⁷, Benjamin Fournier⁸, Brigitte Bader-Meunier⁹, Christopher Troedson¹⁰, Gavin CLeary¹¹, Helena Buso¹², Jacqueline Dalby-Payne¹³, Ranade Prajakta¹⁴, Katrien Jansen¹⁵, Lien De Somer¹⁶, Marie-Louise Fremond¹⁷, Pimple Pallavi¹⁴, Melanie Wong¹⁸, Russel Dale¹⁰, Carine Wouters¹⁶, PIERRE QUARTIER¹⁹, Raju Khubchandani²⁰ and Yanick Crow⁵, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ²NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, ³Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, ⁴Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France, Paris, France, ⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom, Edinburgh, United Kingdom, ⁶Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, ⁷: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, Newcastle, United Kingdom, ⁸Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, France, ⁹Necker Hospital, Assistance Publique Hopitaux de Paris, Paris, France, ¹⁰T. Y. Nelson Department of Neurology and Neurosurgery, Children's Hospital at Westmead, Westmead, New South Wales, and University of Sydney, Australia, Sydney, Australia, ¹¹: Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, Liverpool, United Kingdom, ¹²Department of Medicine - DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹³Specialty of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Australia, Sydney, Australia, ¹⁴NH SRCC hospital, Department of Pediatric Rheumatology, Mumbai, Maharashtra, India, Mumbai, India, ¹⁵Division of Pediatric Neurology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁶Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven, Belgium, Leuven, Belgium, ¹⁷Paediatric Immunology-Hematology and Rheumatology Unit, Necker Hospital, APHP Centre, Université Paris-Cité, Paris, France, Paris, United Kingdom, ¹⁸Department of Allergy and Immunology, Children's Hospital at Westmead, Westmead, Australia, Westmead, Australia, ¹⁹Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France, ²⁰SRCC Childrens Hospital, Mumbai, India
Background/Purpose: To report on the largest cohort of C1Q deficient (C1QDef ) patients; to investigate the activation of Type 1 interferon pathway in the blood…
Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Anca Askanase¹, Edward Vital², Oliver Meier³, Armando Turchetta⁴, Huiyan (Ashley) Mao⁴, Justine Maller⁵, Jorge A. Ross Terres⁶ and Maria Dall'Era⁷, ¹Columbia University Medical Center, New York, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc,, San Francisco, CA, ⁶Genentech, Inc,, San Francisco, ⁷UCSF, Corte Madera, CA
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Marta Hernández-Díaz¹, Iván Ferraz-Amaro², Sergio Santos-Concepción³, Javier Castro³, Vanesa Hernandez⁴, Beatriz Tejera Segura⁵, Cristina Luna⁶, Esmeralda Delgado-Frías² and Federico Diaz-González², ¹Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ²Hospital Universitario de Canarias, La Laguna, Spain, ³Universidad de La Laguna, La Laguna, Spain, ⁴Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ⁶Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 0685 • ACR Convergence 2023
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
Duvuru Geetha¹, Anisha Dua², Huibin Yue³, Carlo Salvarani⁴, David Jayne⁵ and Peter Merkel⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, IL, ³Amgen, Inc., Thousand Oaks, CA, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: The randomized, double-blind, double-dummy, controlled Phase 3 ADVOCATE trial tested whether avacopan, an oral selective C5a receptor inhibitor approved for the treatment of ANCA-associated…
Abstract Number: 2494 • ACR Convergence 2023
Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis
Salem Almaani¹, Arnon Arazi², Huijuan Song³, Pearlly Yan³, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Samir Parikh³ and Brad Rovin³, ¹Ohio State University Medical Center, Columbus, OH, ²Broad Institute of MIT and Harvard, Melrose, MA, ³Ohio State University, Columbus, OH
Background/Purpose: The role of complement in patients with ANCA-associated vasculitis (AAV) has been increasingly appreciated and led to the use of complement system antagonists as…
Abstract Number: 0686 • ACR Convergence 2023
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
David Jayne¹, Duvuru Geetha², Christian Pagnoux³, Sebastian Sattui⁴ and Peter Merkel⁵, ¹University of Cambridge, Cambridge, United Kingdom, ²Johns Hopkins University, Baltimore, MD, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Older adults are at increased risk of glucocorticoid (GC)-related toxicity; minimization of GCs is a major focus for treatment of patients with ANCA-associated vasculitis…
Abstract Number: 0687 • ACR Convergence 2023
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
Georgina Espigol-Frigole¹, Maria C Cid², Juliana Bordignon Draibe³, Maria Carmen Prados⁴, Elena Guillen⁵, Ana Huerta⁶, Javier Villacorta⁷, Cristina Vega⁸, Judith Martins⁹, Borja Gracia¹⁰ and Enrique Morales¹¹, ¹Autoimmune Diseases. Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Clinic Barcelona, Barcelona, Spain, ³Hospital Bellvitge, Barcelona, Spain, ⁴Hospital Torrecárdenas, Almeria, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Puerta de Hierro, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital La Paz, Madrid, Spain, ⁹Hospital de Getafe, Madrid, Spain, ¹⁰Hospital Lozano Blesa, Zaragoza, Spain, ¹¹Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: ANCA-associated vasculitis are chronic and relapsing diseases. Relapses are frequently associated with organ damage accrual as a consequence of disease activity or treatment-related side…
Abstract Number: 0688 • ACR Convergence 2023
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Federico Alberici¹, Carlo Salvarani², Christine Chan³, Achim Obergfell⁴ and Tamara Popov⁴, ¹Universita degli Studi di Brescia, Brescia, Italy, ²Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³CSL Vifor, Redwood City, CA, ⁴CSL Vifor, Glattbrugg, Switzerland
Background/Purpose: Avacopan, a selective C5aR1 inhibitor, has demonstrated efficacy and safety over 52 weeks in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. However, efficacy and…
Abstract Number: 0736 • ACR Convergence 2023
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics
Juan Vargas¹, Ian Mantel², Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao³, Susan Goodman⁵, Kevin Deane¹, The Accelerating Medicines Partnership SLE/RA¹, Jennifer Anolik⁶, Michael Brenner⁴, Soumya Raychaudhuri³, Jennifer Seifert⁷, Michael Holer¹, Laura Donlin⁵ and Fan Zhang⁸, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Weill Cornell Medicine, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶University of Rochester Medical Center, Rochester, NY, ⁷the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, ⁸University of Colorado, Aurora, CO

Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].